tirzepatide and liver hits two receptors. Semaglutide hits one. The feels the difference. Both drugs work in MASH. The question is whether the second receptor — GIP — adds meaningful hepatic benefit beyond Can tirzepatide (glucagon-like peptide-1 receptor

These include: Nausea very common (may affect more than 1 in 10 people) Vomiting and diarrhoea common (may affect up to 1 in 10 people), especially when starting treatment or increasing the dose Abdominal pain and bloating related to the slowing of gastric emptying Reduced appetite common and may contribute to weight reduction Constipation common according to the product information These gastrointestinal symptoms are usually mild to moderate and often improve over time as the body adapts to the medication

May your medication stay cold, your flights stay smooth, and your protocol stay uninterrupted.

Myth: Taking more glutathione will lead to faster results

Strain it using a strainer, and the juice is ready

Injectable NAD and nicotinamide-riboside study Key Takeaway GHK-Cu vs NAD+ comparison

The study highlights GHK-Cus ability to inhibit the formation of reactive carbonyl species (RCS), detoxify toxic products of lipid peroxidation, and protect keratinocytes from UVB radiation